The latest update is out from HUTCHMED (China) Limited ( (HK:0013) ).
HUTCHMED (China) Limited announced the vesting of non-performance based awards under its Long Term Incentive Plan, granted to Dr. Weiguo Su, the company’s Executive Director, CEO, and Chief Scientific Officer. This vesting of awards signifies the company’s commitment to rewarding its leadership, potentially impacting its operational focus and stakeholder confidence positively.
More about HUTCHMED (China) Limited
HUTCHMED (China) Limited is an innovative, commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases. The company has successfully marketed its first three medicines in China, with one also approved in the US, Europe, and Japan.
YTD Price Performance: 0.85%
Average Trading Volume: 49,098
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £2.1B
For an in-depth examination of 0013 stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com